Pharmacokinetics and Dose Optimization of Ethambutol in Children on First-Line Antituberculosis Therapy: An Individual Patient Data Meta-Analysis
Abstract
BACKGROUND: Tuberculosis affects over one million children annually. Ethambutol (EMB) is a key component of first-line therapy, but comprehensive pediatric pharmacokinetic studies have been lacking. METHODS: EMB concentrations and individual-level patient data from 3 studies were analyzed using nonlinear mixed effects modeling. Simulations compared current World Health Organization (WHO)-recommended doses and model-informed optimized doses. Target exposure distribution (area under the curve, 13.8-17.7 mg·h/L), which had been previously established in adult clinical trials, guided dose optimization. RESULTS: A total of 220 participants (0.2-15 years; 3.6 and 43.0 kg) contributed 1085 plasma EMB concentrations for model development. Weight effects were incorporated for clearance (CL), intercompartmental CL, and volumes of distribution in central and peripheral compartments. Age affected CL through a maturation function. Simulations indicated children weighing <25 kg had median exposures below target exposure distribution at current WHO-recommended doses. Optimized weight-band dosing would increase doses in approximately 40.5% of the patients, with an additional 5% potentially benefiting. CONCLUSIONS: Our individual patient data meta-analysis supports the revision of current pediatric EMB dosing guidelines for the treatment of tuberculosis. Our findings aim to ensure adequate drug exposure across all pediatric weight bands, while also accounting for toxicity and challenges…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 220 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.